PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Rivaroxaban - Prevention of atherothrombotic events - coronary or peripheral artery disease

PAD Profile : Rivaroxaban - Prevention of atherothrombotic events - coronary or peripheral artery disease

Keywords :
anticoagulant cards, anticoagulant alert cards, NOAC, DOAC, direct oral anticoagulant, PAD, coronary artery disease, CAD, arterial disease
Brand Names Include :
Xarelto

Traffic Light Status

Status 1 of 1.

Status :
Green
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 July 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agree that rivaroxaban is a treatment option for people with coronary or peripheral artery disease in line with NICE TA 607.

Rivaroxaban will be given a GREEN traffic light status for this indication

The APC recognises that the difference between the benefits and risks is small, but the APC supports prescribing for PAD or CAD, in those patients where the clinicians have identified (with shared decision making, and as part of a routine review) that the patient is likely to benefit from treatment with rivaroxaban.

Associated BNF Codes

02. Cardiovascular System
02.08.02. Oral anticoagulants
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More